Ablynx’s vobarilizumab fails to meet primary endpoint in phase II lupus study

This article was originally published here

Ablynx’s lupus erythematosus treatment vobarilizumab has failed to meet primary endpoint in the phase II dose-ranging study.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply